Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Biogen

Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact

Eisai Co Ltd (OTC:ESALY) is giving up its right to share in profits from Aduhelm (aducanumab-avwa), which was developed in partnership with Biogen Inc (NASDAQ:BIIB). Biogen and Eisai have amended their agreement to give Biogen full authority to make regulatory and sales decisions regarding Aduhelm. From 2023, Eisai will receive royalties starting at 2% of…

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Biogen Posts New Updates Across its Spinraza SMA Research Program

Biogen Posts New Updates Across its Spinraza SMA Research Program

Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and NURTURE studies.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma

Biogen Inc (NASDAQ: BIIB) shares are now trading notably off their all-time high of $468.55 hit on June 7, achieved on the back of Aduhel

Expert Ratings For Biogen

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Inside the tactical tug of war over the controversial Alzheimer’s drug

The drug industry, patient advocates and congressional Republicans have all attacked federal officials’ decision to decline routine Medicare coverage for a controversial Alzheimer’s drug. They’ve gone as far as to accuse them of tacit racism, ageism and discrimination against the disabled — and hinted at a lawsuit — over the…

Tribune News Service

Patients’ groups, progressives square off over Medicare Alzheimer’s decision

WASHINGTON — Advocates on both sides of a debate over dramatically restricting Medicare’s coverage of an expensive and controversial Alzheimer’s treatment are waging competing campaigns to influence a final decision in April.

Tribune News Service

inkl

Read news from The Economist, FT, and more,
with one subscription

Patients' groups, progressives square off over Medicare Alzheimer's decision - Roll Call

Patients' groups, progressives square off over Medicare Alzheimer's decision - Roll Call

Competing campaigns look to influence the debate over dramatically restricting coverage of a controversial treatment drug Aduhelm.

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar

Here's a roundup of top developments in the biotech space over the last 24 hours:

Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes

Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm (aducanumab).

What 24 Analyst Ratings Have To Say About Biogen

What 24 Analyst Ratings Have To Say About Biogen

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Analyst Ratings For Biogen

Analyst Ratings For Biogen

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

Biogen's Return On Capital Employed Insights

Biogen's Return On Capital Employed Insights

Benzinga Pro data, Biogen (NASDAQ:BIIB) reported Q4 sales of $2.73 billion. Earnings fell to a loss of $20.50 million, resulting in a 106.44% decrease from last quarter. In Q3, Biogen earned $318.10 million, and total sales reached $2.78 billion.

Get all your
news in one place.

100's of premium titles.
One news app.

Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus

Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $

Biogen: Q4 Earnings Insights

Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Why Biogen Shares Are Sliding Today

Biogen Inc (NASDAQ: BIIB) is trading lower Thursday morning after the company announced worse-than-expected fourth-quarter earnings results and issued guidance below estimates.

The Independent UK

Biogen's 2022 outlook leaves investors wanting, shares slip

Biogen expects “minimal” revenue this year from its Alzheimer’s treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immediate criticism from doctors and patient advocates

Get all your
news in one place.

100's of premium titles.
One news app.

Recap: Biogen Q4 Earnings

Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Earnings Preview For Biogen

Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will likely report an Earnings Per Share (EPS) of $3.40.

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab

Biogen Inc (NASDAQ: BIIB) has

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron

Here's a roundup of top developments in the biotech space over the last 24 hours:

Biogen Sells Biosimilar-Venture Stake To Samsung Biologics For $2.3B

Biogen Inc (NASDAQ: BIIB) is selling its stake in a pharmaceutical joint venture with the South Korean conglomerate Samsung for $2.3 billion.

1 … 5 6 7 8

Organisations

Securities and Exchange Commission

Federal Trade Commission

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play